The startup is advancing a drug licensed from China’s Hengrui Pharma that it claims could be “best-in-class” among a group of similar treatments for hypertrophic cardiomyopathy.
The startup is advancing a drug licensed from China’s Hengrui Pharma that it claims could be “best-in-class” among a group of similar treatments for hypertrophic cardiomyopathy.
– Mean weight loss of 19.2%I at 6 mg with no plateau and favorable safety profile in 48-week Phase 3 clinical trial – – Data builds on previously reported Phase 2 results that showed mean weight loss of 23.6%I at 8 mg at week 36 with no plateau – – NDA submitted in China by Hengrui; Kailera plans to start global Phase 3 trials by year-end evaluating multiple maintenance doses including 8 mg – SHAN...
– Mean weight loss of 19.2%I at 6 mg with no plateau and favorable safety profile in 48-week Phase 3 clinical trial – – Data builds on previously reported Phase 2 results that showed mean weight loss of 23.6%I at 8 mg at week 36 with no plateau – – NDA submitted in China by Hengrui; Kailera plans to start global Phase 3 trials by year-end evaluating multiple maintenance doses including 8 mg – SHANGHAI and WALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Hengrui Pharma (Hengrui), a global pharma